drugset / Trial / NCT01342198

An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet

NCT01342198

Phase 1 Completed 18 enrolled Viatris Inc.
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to 1) evaluate the extent of absorption of a single dose of a pregabalin controlled release tablet with and without coadministration of erythromycin and 2) evaluate the safety and tolerability of a single dose of a pregabalin controlled release tablet with and without coadministration of erythromycin.

Timeline

Start
2011-06
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Erythromycin Small molecule 500 mg
Subject Pregabalin Small molecule 330 mg Oral

Indications

No indication recorded.